Table 4. Baseline characteristics after propensity score matching between PS and other groups.
| CTA | PS | P value | EVAL | PS | P value | PAN | PS | P value | PEPA | PS | P value | PES | PS | P value | PMMA | PS | P value | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n (%) | 10,592 | 10,592 | 571 | 571 | 764 | 764 | 4,683 | 4,683 | 7,480 | 7,480 | 3,835 | 3,835 | ||||||
| Age (years) | 67 ± 12 | 67 ± 12 | 0.539 | 70 ± 11 | 70 ± 11 | 0.689 | 66 ± 12 | 66 ± 12 | 0.283 | 66 ± 12 | 66 ± 12 | 0.283 | 62 ± 12 | 62 ± 12 | 0.835 | 68 ± 11 | 68 ± 11 | 0.081 |
| Sex (% Female) | 38.0 | 37.4 | 0.356 | 53.4 | 52 | 0.635 | 40.9 | 41.6 | 0.426 | 40.9 | 41.6 | 0.426 | 35.8 | 35.3 | 0.528 | 42.6 | 42.9 | 0.764 |
| HD duration (years) | 6 [3–10] | 6 [3–10] | 0.364 | 5 [3–10] | 5 [3–9] | 0.426 | 6 [4–11] | 6 [4–11] | 0.978 | 6 [4–11] | 6 [4–11] | 0.978 | 7 [4–12] | 7 [4–12] | 0.531 | 6 [3–11] | 6 [4–11] | 0.456 |
| Presence of DM | 37.2 | 36.5 | 0.339 | 36.4 | 36.6 | 0.859 | 32.4 | 32.2 | 0.859 | 32.4 | 32.2 | 0.859 | 29.0 | 28.6 | 0.563 | 33.0 | 33.0 | 1.00 |
| Comorbidity of CVD | 27.6 | 27.1 | 0.405 | 30.6 | 31.0 | 0.898 | 24.1 | 23.6 | 0.577 | 24.1 | 23.6 | 0.577 | 22.8 | 23.3 | 0.393 | 29.7 | 29.7 | 0.942 |
| BMI (kg/m2) | 21.1 ± 3.6 | 21.1 ± 3.5 | 0.355 | 20.2 ± 3.4 | 20.1 ± 3.5 | 0.682 | 20.8 ± 3.3 | 20.8 ± 3.3 | 0.487 | 20.8 ± 3.3 | 20.8 ± 3.3 | 0.487 | 21.4 ± 3.5 | 21.4 ± 3.6 | 0.442 | 20.5 ± 3.2 | 20.6 ± 3.3 | 0.859 |
| Hb (g/dL) | 10.5 ± 1.2 | 10.5 ± 1.2 | 0.469 | 10.3 ± 1.2 | 10.3 ± 1.6 | 0.946 | 10.4 ± 1.3 | 10.4 ± 1.2 | 0.919 | 10.4 ± 1.3 | 10.4 ± 1.2 | 0.919 | 10.5 ± 1.2 | 10.5 ± 1.2 | 0.712 | 10.2 ± 1.2 | 10.3 ± 1.2 | 0.142 |
| Alb (g/dL) | 3.6 ± 0.4 | 3.6 ± 0.5 | 0.072 | 3.5 ± 0.4 | 3.5 ± 0.5 | 0.885 | 3.6 ± 0.4 | 3.6 ± 0.4 | 0.247 | 3.6 ± 0.4 | 3.6 ± 0.4 | 0.247 | 3.8 ± 0.4 | 3.8 ± 0.4 | 0.502 | 3.6 ± 0.4 | 3.6 ± 0.4 | 0.691 |
| TC (mg/dL) | 155 ± 35 | 155 ± 36 | 0.230 | 158 ± 39 | 159 ± 39 | 0.845 | 157 ± 36 | 157 ± 36 | 0.485 | 157 ± 36 | 157 ± 36 | 0.485 | 153 ± 33 | 153 ± 34 | 0.367 | 162 ± 37 | 163 ± 38 | 0.183 |
| Ca (mg/dL) | 9.0 ± 0.8 | 9.0 ± 0.8 | 0.068 | 8.9 ± 0.8 | 8.9 ± 0.8 | 0.517 | 9.0 ± 0.8 | 9.0 ± 0.8 | 0.517 | 9.0 ± 0.8 | 9.0 ± 0.8 | 0.517 | 9.1 ± 0.8 | 9.1 ± 0.8 | 0.528 | 8.9 ± 0.8 | 8.9 ± 0.8 | 0.604 |
| P (mg/dL) | 5.3 ± 1.4 | 5.3 ± 1.4 | 0.053 | 5.0 ± 1.4 | 5.0 ± 1.4 | 0.864 | 5.3 ± 1.4 | 5.3 ± 1.4 | 0.641 | 5.3 ± 1.4 | 5.3 ± 1.4 | 0.641 | 5.4 ± 1.5 | 5.4 ± 1.5 | 0.801 | 5.2 ± 1.4 | 5.2 ± 1.4 | 0.562 |
| β2M (mg/L) | 27.8 ± 7.0 | 27.9 ± 6.8 | 0.414 | 29.6 ± 7.7 | 29.4 ± 8.4 | 0.731 | 27.2 ± 6.5 | 27.0 ± 6.3 | 0.197 | 27.2 ± 6.5 | 27.0 ± 6.3 | 0.197 | 27.2 ± 6.4 | 27.2 ± 6.2 | 0.961 | 29.3 ± 6.9 | 29.4 ± 7.2 | 0.574 |
| CRP (mg/dL) | 0.13 [0.05–0.40] | 0.12 [0.06–0.38] | 0.530 | 0.13 [0.05–0.43] | 0.16 [0.06–0.47] | 0.583 | 0.11 [0.05–0.35] | 0.11 [0.05–0.32] | 0.583 | 0.11 [0.05–0.35] | 0.11 [0.05–0.32] | 0.583 | 0.11 [0.05–0.30] | 0.11 [0.05–0.34] | 0.365 | 0.12 [0.06–0.40] | 0.14 [0.06–0.41] | 0.691 |
| Kt/V | 1.43 ± 0.27 | 1.43 ± 0.29 | 0.191 | 1.34 ± 0.28 | 1.33 ± 0.27 | 0.501 | 1.44 ± 0.27 | 1.45 ± 0.29 | 0.501 | 1.44 ± 0.27 | 1.45 ± 0.29 | 0.501 | 1.47 ± 0.29 | 1.47 ± 0.29 | 0.946 | 1.40 ± 0.27 | 1.40 ± 0.27 | 0.832 |
| nPCR (g/kg/day) | 0.87 ± 0.17 | 0.87 ± 0.17 | 0.858 | 0.84 ± 0.17 | 0.83 ± 0.17 | 0.649 | 0.88 ± 0.17 | 0.88 ± 0.17 | 0.672 | 0.88 ± 0.17 | 0.88 ± 0.17 | 0.672 | 0.90 ± 0.18 | 0.90 ± 0.18 | 0.512 | 0.86 ± 0.17 | 0.85 ± 0.18 | 0.125 |
| %CGR (%) | 98 ± 26 | 98 ± 26 | 0.663 | 87 ± 27 | 87 ± 28 | 0.975 | 100 ± 26 | 100 ± 29 | 0.975 | 100 ± 26 | 100 ± 29 | 0.975 | 103 ± 24 | 103 ± 27 | 0.947 | 96 ± 26 | 96 ± 26 | 0.621 |
Alb, serum albumin; β2M, β2-microglobulin; BMI, body mass index; Ca, calcium; CRP, C-reactive protein; CTA, cellulose triacetate; CVD, cardiovascular disease; DM, diabetes mellitus; EVAL, ethylene vinyl alcohol; nPCR, normalized protein catabolic rate; P, phosphate; PAN, polyacrylonitrile; PEPA, polyester polymer alloy; PES, polyethersulfone; PMMA, polymethylmethacrylate; PS, polysulfone, %CGR, % creatinine generation rate.